Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and targeted treatment of autoimmune and inflammatory diseases.

[1]  A. Zangrillo,et al.  Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study , 2020, Annals of the Rheumatic Diseases.

[2]  M. Crow,et al.  Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series , 2020, Arthritis & rheumatology.

[3]  M. Massari,et al.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[4]  R. Scrivo,et al.  Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients , 2020, Frontiers in Immunology.

[5]  J. Hernández-Rodríguez,et al.  Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment , 2020, Rheumatology.

[6]  G. Chatellier,et al.  Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.

[7]  A. Zangrillo,et al.  Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study , 2020, European Journal of Internal Medicine.

[8]  L. Bonnemains,et al.  Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic , 2020, Circulation.

[9]  C. Molteni,et al.  Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report , 2020, International Journal of Infectious Diseases.

[10]  M. Netea,et al.  Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis , 2020, Cell Host & Microbe.

[11]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[12]  G. Antonucci,et al.  Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease , 2020, Journal of Allergy and Clinical Immunology.

[13]  G. Costantino,et al.  Use of anakinra in severe COVID-19: A case report , 2020, International Journal of Infectious Diseases.

[14]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[15]  D. Buonsenso,et al.  Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra , 2020, Frontiers in Pediatrics.

[16]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[17]  E. Bergot,et al.  Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series , 2020, Annals of the Rheumatic Diseases.

[18]  R. Priori,et al.  COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? , 2020, Autoimmunity Reviews.

[19]  G. Emmi,et al.  Behçet: the syndrome. , 2020, Rheumatology.

[20]  S. Maskatia,et al.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. , 2020, Hospital pediatrics.

[21]  D. McGonagle,et al.  The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.

[22]  Jefree J. Schulte,et al.  Connective Tissue Disease Related Interstitial Lung Disease. , 2020, Surgical pathology clinics.

[23]  A. Hoischen,et al.  Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout , 2020, Annals of the rheumatic diseases.

[24]  C. Doglioni,et al.  Erdheim‐Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer , 2020, Journal of leukocyte biology.

[25]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[26]  G. Cavalli,et al.  Autophagy and protein secretion. , 2020, Journal of molecular biology.

[27]  S. Shivaswamy,et al.  Neutralization of IL-1α ameliorates Crohn’s disease-like ileitis by functional alterations of the gut microbiome , 2019, Proceedings of the National Academy of Sciences.

[28]  G. Hatemi,et al.  Treating the Different Phenotypes of Behçet's Syndrome , 2019, Front. Immunol..

[29]  Y. Adler,et al.  Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study , 2019, European journal of preventive cardiology.

[30]  C. Dinarello.  The IL-1 family of cytokines and receptors in rheumatic diseases , 2019, Nature Reviews Rheumatology.

[31]  B. Ghanim,et al.  IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis , 2019, European Respiratory Journal.

[32]  S. Ghosh,et al.  Developmentally Regulated Innate Immune NFκB Signaling Mediates IL-1α Expression in the Perinatal Murine Lung , 2019, Front. Immunol..

[33]  Scott R. Presnell,et al.  Infants with evolving bronchopulmonary dysplasia demonstrate monocyte-specific expression of IL-1 in tracheal aspirates. , 2019, American journal of physiology. Lung cellular and molecular physiology.

[34]  R. Consolini,et al.  SAT0490 IL-1 BLOCKADE IN PEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY ON THE ITALIAN COHORT , 2019, Saturday, 15 June 2019.

[35]  G. Hatemi,et al.  Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils , 2019, Front. Immunol..

[36]  R. Cimaz,et al.  Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings , 2019, Journal of Medical Case Reports.

[37]  F. Vincent,et al.  Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis , 2019, Clinical & translational immunology.

[38]  M. Bennett,et al.  The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin , 2019, Immunity.

[39]  B. Palmer,et al.  Role for nuclear interleukin-37 in the suppression of innate immunity , 2019, Proceedings of the National Academy of Sciences.

[40]  E. Seyahi.  Phenotypes in Behçet’s syndrome , 2019, Internal and Emergency Medicine.

[41]  N. Taddei,et al.  Behçet’s syndrome as a tool to dissect the mechanisms of thrombo‐inflammation: clinical and pathogenetic aspects , 2018, Clinical and experimental immunology.

[42]  E. Silvestri,et al.  Vascular Behçet’s syndrome: an update , 2018, Internal and Emergency Medicine.

[43]  S. Smeekens,et al.  The Inter-Relationship of Platelets with Interleukin-1β-Mediated Inflammation in Humans , 2018, Thrombosis and Haemostasis.

[44]  G. Cavalli,et al.  Anakinra Therapy for Non-cancer Inflammatory Diseases , 2018, Front. Pharmacol..

[45]  L. Garratt,et al.  Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[46]  M. Curley,et al.  Interleukin-1 Receptor Antagonist Is Associated With Pediatric Acute Respiratory Distress Syndrome and Worse Outcomes in Children With Acute Respiratory Failure* , 2018, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[47]  E. Pretorius,et al.  Simultaneous presence of hypercoagulation and increased clot lysis time due to IL‐1&bgr;, IL‐6 and IL‐8 , 2018, Cytokine.

[48]  A. Iwasaki,et al.  An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication. , 2018, Molecular cell.

[49]  P. Salice,et al.  Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase , 2018, Italian Journal of Pediatrics.

[50]  P. Salice,et al.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks , 2018, Italian Journal of Pediatrics.

[51]  A. Galluzzo,et al.  Advances in medical therapy for pericardial diseases , 2018, Expert review of cardiovascular therapy.

[52]  T. Kanneganti,et al.  Cutting Edge: Dysregulated CARD9 Signaling in Neutrophils Drives Inflammation in a Mouse Model of Neutrophilic Dermatoses , 2018, The Journal of Immunology.

[53]  P. Libby,et al.  Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1&agr; and Cathepsin G , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[54]  R. Cimaz,et al.  The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. , 2018, Autoimmunity reviews.

[55]  C. Borg,et al.  Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study , 2018, Oncoimmunology.

[56]  C. Campochiaro,et al.  Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. , 2018, Annals of internal medicine.

[57]  V. Pascual,et al.  IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. , 2018, Cancer research.

[58]  D. Seals,et al.  Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue , 2018, The Journal of Biological Chemistry.

[59]  S. Schrader,et al.  Comparative analysis on the dynamic of lacrimal gland damage and regeneration after Interleukin‐1&agr; or duct ligation induced dry eye disease in mice , 2018, Experimental eye research.

[60]  S. Awasthi,et al.  Interleukin 1 receptor antagonist (IL1RA) gene polymorphism and levels associated with adverse outcome in severe community‐acquired pneumonia in children: A hospital‐based study in India , 2018, Pediatric pulmonology.

[61]  C. Campochiaro,et al.  Myocarditis: An Interleukin-1-Mediated Disease? , 2018, Front. Immunol..

[62]  L. Buckley,et al.  Interleukin-1 blockade in cardiovascular diseases: a clinical update , 2018, European heart journal.

[63]  A. Tomelleri,et al.  Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease , 2018, Front. Immunol..

[64]  K. Chung,et al.  Interleukin-1α Mediates Ozone-Induced Myeloid Differentiation Factor-88-Dependent Epithelial Tissue Injury and Inflammation , 2018, Front. Immunol..

[65]  A. di Lenarda,et al.  Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism , 2018, Internal and Emergency Medicine.

[66]  D. Robertson,et al.  Redefining the ancestral origins of the interleukin-1 superfamily , 2018, Nature Communications.

[67]  C. Doglioni,et al.  The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease , 2018, Oncoimmunology.

[68]  L. French,et al.  Are neutrophilic dermatoses autoinflammatory disorders? , 2018, The British journal of dermatology.

[69]  B. Pollo,et al.  Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim–Chester disease , 2018, Journal of Neurology.

[70]  C. Dinarello.  Overview of the IL‐1 family in innate inflammation and acquired immunity , 2018, Immunological reviews.

[71]  G. Cavalli,et al.  Suppression of inflammation and acquired immunity by IL‐37 , 2018, Immunological reviews.

[72]  F. Skopouli,et al.  How stress contributes to autoimmunity—lessons from Sjögren's syndrome , 2018, FEBS letters.

[73]  L. Joosten,et al.  Biology of IL‐38 and its role in disease , 2018, Immunological reviews.

[74]  C. Garlanda,et al.  Tuning inflammation and immunity by the negative regulators IL‐1R2 and IL‐1R8 , 2018, Immunological reviews.

[75]  T. Kanneganti,et al.  Function and regulation of IL‐1α in inflammatory diseases and cancer , 2018, Immunological reviews.

[76]  C. Garlanda,et al.  IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy , 2018, Immunological reviews.

[77]  M. Argyropoulou,et al.  MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. , 2017, The Journal of investigative dermatology.

[78]  M. Bianchi,et al.  High‐mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair , 2017, Immunological reviews.

[79]  F. Gaita,et al.  Acute and Recurrent Pericarditis. , 2017, Cardiology clinics.

[80]  E. Furfine,et al.  Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease , 2017, Eye & contact lens.

[81]  J. Kramer,et al.  Innate immunity in Sjögren's syndrome. , 2017, Clinical immunology.

[82]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[83]  M. Boubaya,et al.  Mapping and predicting mortality from systemic sclerosis , 2017, Annals of the rheumatic diseases.

[84]  P. Calverley,et al.  A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease , 2017, Respiratory Research.

[85]  Seamus J. Martin,et al.  Neutrophil extracellular traps can serve as platforms for processing and activation of IL‐1 family cytokines , 2017, The FEBS journal.

[86]  G. Ferraccioli,et al.  Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis , 2017, Medicine.

[87]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis , 2017, The Lancet.

[88]  A. Abbate,et al.  Reduction of Myocardial Ischemia–Reperfusion Injury by Inhibiting Interleukin-1 Alpha , 2017, Journal of cardiovascular pharmacology.

[89]  C. Dinarello,et al.  Alarmins: Feel the Stress , 2017, The Journal of Immunology.

[90]  L. Joosten,et al.  Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance , 2017, Proceedings of the National Academy of Sciences.

[91]  L. Cabrini,et al.  Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure , 2017, Front. Immunol..

[92]  P. Mohanty,et al.  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. , 2017, The Lancet. Oncology.

[93]  G. Guggino,et al.  Interstitial lung disease in systemic sclerosis: current and future treatment , 2017, Rheumatology International.

[94]  L. Joosten,et al.  Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. , 2016, Rheumatology.

[95]  M. Sormani,et al.  Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. , 2016, JAMA.

[96]  O. Abdel-Wahab,et al.  Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. , 2016, Blood.

[97]  B. McCrindle,et al.  Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease , 2016, The Journal of Immunology.

[98]  E. Latz,et al.  HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins , 2016, Cellular & Molecular Immunology.

[99]  R. Sorrentino,et al.  IL-1α and IL-1β-producing macrophages populate lung tumor lesions in mice , 2016, Oncotarget.

[100]  F. Pappalardo,et al.  Treating Life-Threatening Myocarditis by Blocking Interleukin-1* , 2016, Critical care medicine.

[101]  D. Shayakhmetov,et al.  Interleukin 1α and the inflammatory process , 2016, Nature Immunology.

[102]  D. Postma,et al.  Interleukin-1α drives the dysfunctional cross-talk of the airway epithelium and lung fibroblasts in COPD , 2016, European Respiratory Journal.

[103]  P. Howarth,et al.  IL-1α mediates cellular cross-talk in the airway epithelial mesenchymal trophic unit , 2016, Tissue barriers.

[104]  Q. Yao,et al.  Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature. , 2016, Seminars in arthritis and rheumatism.

[105]  C. Becerra,et al.  A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients. , 2016 .

[106]  C. Doglioni,et al.  Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease , 2016, Oncoimmunology.

[107]  J. Newburger,et al.  Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). , 2016, Contemporary clinical trials.

[108]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[109]  P. Cluzel,et al.  Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. , 2016, Blood.

[110]  Richard L. Amdur,et al.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* , 2016, Critical care medicine.

[111]  Rosanna Abbate,et al.  Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease , 2016, Circulation.

[112]  C. Dinarello,et al.  Corrigendum: IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity , 2016, Scientific Reports.

[113]  E. Voronov,et al.  IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer , 2015, Cancer Microenvironment.

[114]  A. Abbate,et al.  Formation of the inflammasome during cardiac allograft rejection. , 2015, International journal of cardiology.

[115]  Y. Iwakura,et al.  Interdependence between Interleukin-1 and Tumor Necrosis Factor Regulates TNF-Dependent Control of Mycobacterium tuberculosis Infection. , 2015, Immunity.

[116]  M. Fishbein,et al.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1&agr; and IL-1&bgr; , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[117]  V. D. Di Crescenzo,et al.  Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1α in an AIM2 inflammasome-dependent manner. , 2015, The American journal of pathology.

[118]  C. Dinarello,et al.  IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity , 2015, Scientific Reports.

[119]  L. Guillevin,et al.  Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy. , 2015, Clinical and experimental rheumatology.

[120]  C. Alessandri,et al.  Interleukin‐36α axis is modulated in patients with primary Sjögren's syndrome , 2015, Clinical and experimental immunology.

[121]  Yan Wang,et al.  Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients , 2015, PloS one.

[122]  I. Komuro,et al.  IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs , 2015, The Journal of cell biology.

[123]  P. Mohanty,et al.  Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer , 2015, Investigational New Drugs.

[124]  J. Bessa,et al.  Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. , 2014, Journal of autoimmunity.

[125]  Bo Gao,et al.  Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis. , 2014, American journal of physiology. Heart and circulatory physiology.

[126]  C. Dinarello.  Interleukin-1α neutralisation in patients with cancer. , 2014, The Lancet. Oncology.

[127]  E. Bruera,et al.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. , 2014, The Lancet. Oncology.

[128]  N. Frangogiannis,et al.  The inflammatory response in myocardial injury, repair, and remodelling , 2014, Nature Reviews Cardiology.

[129]  A. Baldi,et al.  Formation of the inflammasome in acute myocarditis. , 2014, International journal of cardiology.

[130]  M. D’Elios,et al.  Behçet’s syndrome pathophysiology and potential therapeutic targets , 2014, Internal and Emergency Medicine.

[131]  C. Garlanda,et al.  Negative regulatory receptors of the IL-1 family. , 2013, Seminars in immunology.

[132]  C. Garlanda,et al.  The interleukin-1 family: back to the future. , 2013, Immunity.

[133]  A. Hall,et al.  Abstract 14792: The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study , 2013 .

[134]  E. Silvestri,et al.  Vascular Behçet's disease: new insights in the management of thrombosis , 2013, Expert review of cardiovascular therapy.

[135]  P. Corris,et al.  IL-1α released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts , 2013, Mucosal Immunology.

[136]  C. Dinarello,et al.  The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines , 2013, Front. Immunol..

[137]  T. Vijmasi,et al.  Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease , 2013, Molecular vision.

[138]  C. Dinarello,et al.  Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice , 2013, Gut.

[139]  E. Briend,et al.  The Role of Interleukin-1 and Interleukin-18 in Pro-Inflammatory and Anti-Viral Responses to Rhinovirus in Primary Bronchial Epithelial Cells , 2013, PloS one.

[140]  G. Biondi-Zoccai,et al.  Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. , 2013, The American journal of cardiology.

[141]  I. Lundberg,et al.  Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up , 2013, Annals of the rheumatic diseases.

[142]  C. Campochiaro,et al.  Diagnosing Erdheim–Chester disease , 2013, Annals of the rheumatic diseases.

[143]  N. Voelkel,et al.  Interleukin‐1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse , 2013, Experimental physiology.

[144]  J. Maguire,et al.  Intracellular Interleukin-1 Receptor 2 Binding Prevents Cleavage and Activity of Interleukin-1α, Controlling Necrosis-Induced Sterile Inflammation , 2013, Immunity.

[145]  C. Campochiaro,et al.  The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases , 2013, Annals of the rheumatic diseases.

[146]  A. Abbate.  The heart on fire: inflammasome and cardiomyopathy , 2013, Experimental physiology.

[147]  M. Ohtsuki,et al.  Serum levels of interleukin‐1α in patients with systemic sclerosis , 2013, The Journal of dermatology.

[148]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Journal of the American College of Cardiology.

[149]  B. Henderson,et al.  Interleukin-1α is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts , 2012, British Journal of Cancer.

[150]  V. Pascual,et al.  From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines , 2012, Nature Immunology.

[151]  N. Okiyama,et al.  Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice. , 2012, Arthritis and rheumatism.

[152]  H. Yazıcı,et al.  Behçet Syndrome: Is It One Condition? , 2012, Clinical Reviews in Allergy & Immunology.

[153]  Sandeep Sagar,et al.  Myocarditis , 2012, The Lancet.

[154]  R. Omdal,et al.  Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical Trial , 2012, PloS one.

[155]  C. Dinarello,et al.  Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α , 2011, Proceedings of the National Academy of Sciences.

[156]  J. Tschopp,et al.  The inflammasome: an integrated view , 2011, Immunological reviews.

[157]  G. Nash,et al.  Endovascular aneurysm repair reverses the increased titer and the inflammatory activity of interleukin-1α in the serum of patients with abdominal aortic aneurysm. , 2011, Journal of vascular surgery.

[158]  Alberto Mantovani,et al.  Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.

[159]  Umair Khalid,et al.  Hughes-Stovin Syndrome , 2011, Orphanet journal of rare diseases.

[160]  I. Adcock,et al.  Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer , 2011, Thorax.

[161]  S. Johnston,et al.  Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. , 2011, American journal of respiratory and critical care medicine.

[162]  F. Galateau-Sallé,et al.  Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. , 2010, Blood.

[163]  R. Flavell,et al.  IL‐1 receptor‐associated kinase M downregulates DSS‐induced colitis† , 2010, Inflammatory bowel diseases.

[164]  Ying-Ting Chen,et al.  Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren's syndrome. , 2010, The American journal of pathology.

[165]  D. Abraham,et al.  Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. , 2010, The Journal of investigative dermatology.

[166]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[167]  B. McColl,et al.  Platelet interleukin-1alpha drives cerebrovascular inflammation. , 2010, Blood.

[168]  M. Elkabets,et al.  IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. , 2010, International immunology.

[169]  C. Dinarello,et al.  IL‐1: Discoveries, controversies and future directions , 2010, European journal of immunology.

[170]  Kai-Sheng Hsieh,et al.  IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[171]  Y. Carmi,et al.  Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation , 2010, Proceedings of the National Academy of Sciences.

[172]  B. De Paepe,et al.  Role of cytokines and chemokines in idiopathic inflammatory myopathies , 2009, Current opinion in rheumatology.

[173]  N. Turner,et al.  Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. , 2009, American journal of physiology. Heart and circulatory physiology.

[174]  P. Gregersen,et al.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. , 2009, The New England journal of medicine.

[175]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[176]  S. Nandula,et al.  Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. , 2008, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[177]  S. Bayliss,et al.  Neutrophilic Dermatoses in Children , 2008, Pediatric dermatology.

[178]  K. Chatila,et al.  Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. , 2008, The American journal of pathology.

[179]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[180]  J. Lekakis,et al.  Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis , 2008, Circulation.

[181]  Edward McCarthy.  Erdheim-Chester disease , 2008, Definitions.

[182]  D. Pritchard,et al.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. , 2008, Arthritis and rheumatism.

[183]  J. Platt,et al.  Constitutive Repression of Interleukin-1&agr; in Endothelial Cells , 2008, Circulation research.

[184]  T. Montine,et al.  Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. , 2008, Archives of pathology & laboratory medicine.

[185]  K. Rabe,et al.  From COPD to chronic systemic inflammatory syndrome? , 2007, The Lancet.

[186]  S. Akira,et al.  Identification of a key pathway required for the sterile inflammatory response triggered by dying cells , 2007, Nature Medicine.

[187]  C. Kublin,et al.  A single injection of interleukin-1 induces reversible aqueous-tear deficiency, lacrimal gland inflammation, and acinar and ductal cell proliferation. , 2007, Experimental eye research.

[188]  N. Miyasaka,et al.  A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. , 2007, Arthritis and rheumatism.

[189]  C. Dinarello,et al.  Antiviral and immunoregulatory activities of IFN-γ depend on constitutively expressed IL-1α , 2007, Proceedings of the National Academy of Sciences.

[190]  U. Andersson,et al.  Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. , 2007, Arthritis and rheumatism.

[191]  H. Senzaki.  The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases , 2006, Archives of Disease in Childhood.

[192]  S. Kaneko,et al.  Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury , 2006, Critical care medicine.

[193]  R. Uchi,et al.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[194]  N. Rothwell,et al.  Neuroprotective actions of endogenous interleukin‐1 receptor antagonist (IL‐1ra) are mediated by glia , 2006, Glia.

[195]  G. Burmester,et al.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[196]  M. Britschgi,et al.  T Cell-Regulated Neutrophilic Inflammation in Autoinflammatory Diseases1 , 2005, The Journal of Immunology.

[197]  E. Shapiro,et al.  Association between a Novel Human Coronavirus and Kawasaki Disease , 2005, The Journal of infectious diseases.

[198]  Simon C Watkins,et al.  Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. , 2004, The Journal of rheumatology.

[199]  T. Kawakami,et al.  Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. , 2004, Archives of dermatology.

[200]  R. Sobel,et al.  Cytokine and Inducible Nitric Oxide Synthase mRNA Expression during Experimental Murine Cryptococcal Meningoencephalitis , 2004, Infection and Immunity.

[201]  J. Barrett,et al.  Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease. , 2003, Rheumatology.

[202]  M. FitzGerald,et al.  A sequence-based map of the nine genes of the human interleukin-1 cluster. , 2002, Genomics.

[203]  L. Klareskog,et al.  Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. , 2002, Arthritis and rheumatism.

[204]  J. Pugin,et al.  Cytokine balance in the lungs of patients with acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[205]  Y. Kaneda,et al.  Overexpression of Interleukin-1 Receptor Antagonist Provides Cardioprotection Against Ischemia-Reperfusion Injury Associated With Reduction in Apoptosis , 2001, Circulation.

[206]  A. Solomon,et al.  Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. , 2001, Investigative ophthalmology & visual science.

[207]  S. Kumari,et al.  Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. , 2001, Clinical immunology.

[208]  E. Tasali,et al.  Pulmonary manifestations of Behçet's disease , 2001, Thorax.

[209]  M. Muraguchi,et al.  Increased incidence of autoantibodies to interleukin‐1α in rheumatoid arthritis with interstitial lung disease , 2000, Respirology.

[210]  K. Weber,et al.  Infarct scar: a dynamic tissue. , 2000, Cardiovascular research.

[211]  K. Takeda,et al.  Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. , 2000, Journal of the American College of Cardiology.

[212]  A. Wikman,et al.  Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. , 2000, The Journal of rheumatology.

[213]  I. Lundberg,et al.  Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. , 2000, Arthritis and rheumatism.

[214]  S. Pflugfelder,et al.  Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. , 1999, Current eye research.

[215]  T. Wright,et al.  Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A , 1999 .

[216]  I. Lundberg,et al.  New developments in the role of cytokines and chemokines in inflammatory myopathies. , 1998, Current opinion in rheumatology.

[217]  A. Bolstad,et al.  The role of apoptosis in Sjögren's syndrome. , 1998, Annales de medecine interne.

[218]  A. Feldman,et al.  Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. , 1997, Circulation research.

[219]  C. Christov,et al.  Interleukin‐1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes , 1997, Neuropathology and applied neurobiology.

[220]  R. Locksley,et al.  The N-terminal propiece of interleukin 1α is a transforming nuclear oncoprotein , 1997 .

[221]  P. Roux‐Lombard,et al.  IL‐1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjo¨gren's syndrome (SS) , 1996, Clinical and experimental immunology.

[222]  K. Hirayama,et al.  Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-α and interleukin-1β by peripheral blood monocytes in the acute phase of Kawasaki disease , 1996, European Journal of Pediatrics.

[223]  A. Mantovani,et al.  Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function , 1996, The Journal of experimental medicine.

[224]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[225]  C. Fiocchi,et al.  Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. , 1995, Journal of immunology.

[226]  P. Young,et al.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[227]  S. Brown,et al.  Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. , 1993, The Journal of biological chemistry.

[228]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[229]  K. Huebner,et al.  A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. , 1991, The EMBO journal.

[230]  S. Durum,et al.  Membrane IL-1: IL-1 alpha precursor binds to the plasma membrane via a lectin-like interaction. , 1989, Journal of immunology.

[231]  S. Dower,et al.  Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. , 1989, Science.

[232]  P. Pelkonen,et al.  Circulating interleukin-1 beta in patients with Kawasaki disease. , 1988, The New England journal of medicine.

[233]  L. Lachman,et al.  Subcellular localization of human monocyte interleukin 1: evidence for an inactive precursor molecule and a possible mechanism for IL 1 release. , 1987, Journal of immunology.

[234]  G. Habicht,et al.  Isolation and characterization of a primitive interleukin-1-like protein from an invertebrate, Asterias forbesi. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[235]  E. Unanue,et al.  Identification of a membrane-associated interleukin 1 in macrophages. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[236]  S. Mizel,et al.  Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. , 1979, Molecular immunology.

[237]  C. Dinarello,et al.  DEMONSTRATION AND CHARACTERIZATION OF TWO DISTINCT HUMAN LEUKOCYTIC PYROGENS , 1974, The Journal of experimental medicine.

[238]  Jeffrey L. Anderson,et al.  Acute Myocardial Infarction. , 2017, The New England journal of medicine.

[239]  E. Latz,et al.  HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins , 2017 .

[240]  M. Netea,et al.  Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. , 2016, JAMA dermatology.

[241]  R. Jonsson,et al.  Sjögren syndrome , 2016, Nature Reviews Disease Primers.

[242]  M. Stern,et al.  Clinical and Molecular Inflammatory Response in Sjögren Syndrome-Associated Dry Eye Patients Under Desiccating Stress. , 2016, American journal of ophthalmology.

[243]  F. Barone,et al.  Sjögren's syndrome: from pathogenesis to novel therapeutic targets. , 2016, Clinical and experimental rheumatology.

[244]  L. French,et al.  Neutrophilic dermatoses and autoinflammatory diseases with skin involvement—innate immune disorders , 2015, Seminars in Immunopathology.

[245]  Y. H. Lee,et al.  Associations between interleukin-1 polymorphisms and susceptibility to vasculitis: a meta-analysis , 2014, Zeitschrift für Rheumatologie.

[246]  S. Nandula,et al.  Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. , 2013, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[247]  E. Voronov,et al.  Interleukin-1α. , 2013, Seminars in immunology.

[248]  A. Martini,et al.  Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? , 2009, Arthritis and rheumatism.

[249]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[250]  R. Scorza,et al.  T-889C IL-1α promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis , 2006, Clinical Rheumatology.

[251]  M. Muraguchi,et al.  Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. , 2001, The journal of medical investigation : JMI.

[252]  Joan Wilson,et al.  Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[253]  M. Klagsbrun.  The fibroblast growth factor family: structural and biological properties. , 1989, Progress in growth factor research.

[254]  Yoichiro Iwakura,et al.  Interdependence between Interleukin-1 and Tumor Necrosis Factor Regulates TNF-Dependent Control of Mycobacterium tuberculosis Infection , 2022 .